Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends, Growth Outlook

Benign Prostatic Hyperplasia Treatment Market is estimated to increase at a Compounded Annual Growth Rate of 8.2% CAGR over the forecast period from 2024 to 2030

The Benign Prostatic Hyperplasia Treatment Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Drug (Alpha Blockers, 5-Aplha Reductase Inhibitors, Others), By Surgical Treatment (Transurethral Resection of the Prostate (TURP), Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Laser Therapy, Prostatic Stenting, Others).

An Introduction to Benign Prostatic Hyperplasia Treatment Market in 2024

Benign prostatic hyperplasia (BPH) treatment encompasses a range of therapeutic interventions aimed at relieving lower urinary tract symptoms associated with benign enlargement of the prostate gland. In 2024, BPH treatment options include medications, minimally invasive procedures, and surgical interventions, tailored to the severity of symptoms, patient preferences, and clinical indications. Medications such as alpha-blockers, 5-alpha reductase inhibitors, and combination therapy aim to relax the prostate muscles and reduce prostate volume. Minimally invasive procedures such as transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), and prostate artery embolization (PAE) offer alternatives to surgery with fewer risks and shorter recovery times. Surgical interventions such as transurethral resection of the prostate (TURP) and laser prostatectomy provide definitive treatment for patients with severe symptoms or complications. With advancements in technology and surgical techniques, BPH treatment continues to evolve, offering patients personalized approaches to symptom management and improved quality of life.

Market Trend: Minimally Invasive Treatment Modalities

One prominent trend in the benign prostatic hyperplasia (BPH) treatment market is the increasing adoption of minimally invasive treatment modalities. As patients seek alternatives to traditional surgical interventions for BPH, there is a growing demand for minimally invasive procedures that offer fewer complications, shorter recovery times, and improved quality of life. Minimally invasive treatments such as prostate artery embolization (PAE), laser therapy, and transurethral needle ablation (TUNA) are gaining popularity due to their efficacy in relieving BPH symptoms while preserving sexual function and urinary continence. This trend reflects the shift towards patient-centered care and personalized treatment approaches that prioritize minimally invasive options for BPH management, driving innovation and advancements in minimally invasive treatment technologies.

Market Driver: Aging Population and Increasing BPH Prevalence

A significant driver in the benign prostatic hyperplasia treatment market is the aging population and the increasing prevalence of BPH. With demographic shifts towards an older population globally, the incidence and prevalence of BPH are expected to rise, leading to a growing patient population seeking treatment for BPH-related symptoms such as urinary frequency, urgency, and nocturia. As men age, the prostate gland undergoes hyperplastic growth, resulting in urinary tract obstruction and lower urinary tract symptoms (LUTS) characteristic of BPH. The growing burden of BPH among aging men drives the demand for effective treatment options that alleviate symptoms, improve quality of life, and minimize the need for invasive surgical procedures, thus fueling market growth and innovation in BPH treatment modalities.

Market Opportunity: Development of Novel Therapies and Devices

An emerging opportunity in the benign prostatic hyperplasia treatment market is the development of novel therapies and devices. Despite the availability of various treatment options for BPH, including medication, minimally invasive procedures, and surgical interventions, there remains a need for innovative therapies that offer improved efficacy, durability, and safety outcomes. The development of novel pharmacological agents, biologics, and medical devices targeting different pathways involved in BPH pathogenesis presents an opportunity to address unmet medical needs and expand the treatment armamentarium for BPH management. Additionally, there is potential to leverage emerging technologies such as targeted drug delivery systems, tissue engineering, and neuromodulation techniques to develop next-generation therapies that offer personalized and precision treatment approaches for BPH. By investing in research and development efforts to innovate BPH treatments, pharmaceutical companies and medical device manufacturers can capitalize on the growing market demand and contribute to improved patient outcomes in BPH management.

Benign Prostatic Hyperplasia Treatment Market Share Analysis: Laser Therapy is the fastest growing segment over the forecast period to 2030

Among the segments in the Benign Prostatic Hyperplasia (BPH) Treatment Market, the Laser Therapy segment is experiencing the fastest growth. This growth can be attributed to several factors driving the demand for laser therapy as a treatment modality for BPH. Laser therapy offers several advantages over traditional surgical treatments, including reduced invasiveness, shorter recovery times, and decreased risk of complications such as bleeding and urinary incontinence. Additionally, advancements in laser technology, such as the development of holmium and thulium laser systems, have improved the precision, efficacy, and safety of laser procedures for BPH treatment. Laser therapy provides targeted energy delivery to the prostate tissue, resulting in the vaporization or ablation of excess tissue and alleviation of BPH symptoms such as urinary frequency, urgency, and hesitancy. Furthermore, the increasing preference for minimally invasive treatment options among patients and healthcare providers, coupled with the growing aging population and prevalence of BPH-related symptoms, drives the demand for laser therapy as a viable alternative to traditional surgical interventions. As awareness of the benefits of laser therapy for BPH increases and as more healthcare facilities adopt laser technology for prostate procedures, the Laser Therapy segment is expected to sustain its rapid growth in the Benign Prostatic Hyperplasia Treatment Market.

Benign Prostatic Hyperplasia Treatment Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, AbbVie Inc, Advin Health Care, Alembic Pharmaceuticals Ltd, Allium Medical Solutions Ltd, Asahi Kasei Corp, Astellas Pharma Inc, biolitec AG, Boston Scientific Corp, Coloplast Group, Eli Lilly and Company, GlaxoSmithKline plc, IPG Photonics Corp, KARL STORZ SE & Co. KG, Lumenis Ltd, Medifocus Inc, Merck & Co. Inc, Olympus Corp, Pfizer Inc, Pharex HealthCorp Inc, Richard Wolf GmbH, Teleflex Inc, Unilab Pharmaceuticals Inc, Urologix LLC

Benign Prostatic Hyperplasia Treatment Market Segmentation

By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Benign Prostatic Hyperplasia Treatment Market Companies

Abbott Laboratories
AbbVie Inc
Advin Health Care
Alembic Pharmaceuticals Ltd
Allium Medical Solutions Ltd
Asahi Kasei Corp
Astellas Pharma Inc
biolitec AG
Boston Scientific Corp
Coloplast Group
Eli Lilly and Company
GlaxoSmithKline plc
IPG Photonics Corp
KARL STORZ SE & Co. KG
Lumenis Ltd
Medifocus Inc
Merck & Co. Inc
Olympus Corp
Pfizer Inc
Pharex HealthCorp Inc
Richard Wolf GmbH
Teleflex Inc
Unilab Pharmaceuticals Inc
Urologix LLC

Reasons to Buy the Benign Prostatic Hyperplasia Treatment Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Benign Prostatic Hyperplasia Treatment Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Benign Prostatic Hyperplasia Treatment Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Benign Prostatic Hyperplasia Treatment Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Benign Prostatic Hyperplasia Treatment Market Size Outlook, $ Million, 2021 to 2030
3.2 Benign Prostatic Hyperplasia Treatment Market Outlook by Type, $ Million, 2021 to 2030
3.3 Benign Prostatic Hyperplasia Treatment Market Outlook by Product, $ Million, 2021 to 2030
3.4 Benign Prostatic Hyperplasia Treatment Market Outlook by Application, $ Million, 2021 to 2030
3.5 Benign Prostatic Hyperplasia Treatment Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Benign Prostatic Hyperplasia Treatment Industry
4.2 Key Market Trends in Benign Prostatic Hyperplasia Treatment Industry
4.3 Potential Opportunities in Benign Prostatic Hyperplasia Treatment Industry
4.4 Key Challenges in Benign Prostatic Hyperplasia Treatment Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Benign Prostatic Hyperplasia Treatment Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Benign Prostatic Hyperplasia Treatment Market Outlook by Segments
7.1 Benign Prostatic Hyperplasia Treatment Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others

8 North America Benign Prostatic Hyperplasia Treatment Market Analysis and Outlook To 2030
8.1 Introduction to North America Benign Prostatic Hyperplasia Treatment Markets in 2024
8.2 North America Benign Prostatic Hyperplasia Treatment Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Benign Prostatic Hyperplasia Treatment Market size Outlook by Segments, 2021-2030
By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others

9 Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Outlook To 2030
9.1 Introduction to Europe Benign Prostatic Hyperplasia Treatment Markets in 2024
9.2 Europe Benign Prostatic Hyperplasia Treatment Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Benign Prostatic Hyperplasia Treatment Market Size Outlook by Segments, 2021-2030
By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others

10 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Benign Prostatic Hyperplasia Treatment Markets in 2024
10.2 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Benign Prostatic Hyperplasia Treatment Market size Outlook by Segments, 2021-2030
By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others

11 South America Benign Prostatic Hyperplasia Treatment Market Analysis and Outlook To 2030
11.1 Introduction to South America Benign Prostatic Hyperplasia Treatment Markets in 2024
11.2 South America Benign Prostatic Hyperplasia Treatment Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Benign Prostatic Hyperplasia Treatment Market size Outlook by Segments, 2021-2030
By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others
12 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Benign Prostatic Hyperplasia Treatment Markets in 2024
12.2 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market size Outlook by Segments, 2021-2030
By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
AbbVie Inc
Advin Health Care
Alembic Pharmaceuticals Ltd
Allium Medical Solutions Ltd
Asahi Kasei Corp
Astellas Pharma Inc
biolitec AG
Boston Scientific Corp
Coloplast Group
Eli Lilly and Company
GlaxoSmithKline plc
IPG Photonics Corp
KARL STORZ SE & Co. KG
Lumenis Ltd
Medifocus Inc
Merck & Co. Inc
Olympus Corp
Pfizer Inc
Pharex HealthCorp Inc
Richard Wolf GmbH
Teleflex Inc
Unilab Pharmaceuticals Inc
Urologix LLC

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug
Alpha Blockers
5-Aplha Reductase Inhibitors
Others
By Surgical Treatment
Transurethral Resection of the Prostate (TURP)
Transurethral Microwave Thermotherapy (TUMT)
Transurethral Needle Ablation of the Prostate (TUNA)
Laser Therapy
Prostatic Stenting
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)